Thelansis

Primary Biliary Cholangitis (PBC) Market Outlook Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Biliary Cholangitis (PBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Biliary Cholangitis (PBC) Overview Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune cholestatic liver disease characterised by immune-mediated destruction of small intrahepatic bile ducts, driven by autoreactive T-cell targeting of mitochondrial antigens — predominantly the pyruvate dehydrogenase complex E2 subunit — in genetically susceptible individuals, with antimitocho...

Primary Biliary Cholangitis (PBC) Market Outlook Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Biliary Cholangitis (PBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the gr...

Primary Biliary Cholangitis (PBC) Market Outlook Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Biliary Cholangitis (PBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest ...

Primary Biliary Cholangitis (PBC) Market Outlook Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Biliary Cholangitis (PBC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Primary Biliary Cholangitis (PBC) Overview Primary biliary cholangitis (PBC), once known as primary biliary cirrhosis, is a chronic ailment involving progressive damage, inflammation, and eventual destruction of the liver’s small bile ducts. Bile, a crucial digestive fluid produced by the liver, plays a vital role in processing food and expelling toxins, cholesterol, and aged red blood cells from the body...

  Mirum Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough therapy designation to their drug, volixibat, as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC). This designation was granted following positive interim results from the Phase 2b VANTAGE study, which demonstrated statistically significant improvements in pruritus symptoms compared to a placebo for patients treated with volixibat. Publish Date: 10-10-2024   Source: Mirum Pharmaceuticals, Inc. Primary biliary cholangitis (PBC), once known as primary biliary cirrhosis, is a chronic ailment involving progressive damage, inflammation, and eventual destruction of the liver’s small bile ducts. Bile, a crucial digestive fluid produced by the liver, plays a vital role in processing food and expelling toxins, cholesterol, and aged red blood cells from the body. However, when these bile ducts suffer harm, bile accu...

 Primary biliary cholangitis (PBC), once known as primary biliary cirrhosis, is a chronic ailment involving progressive damage, inflammation, and eventual destruction of the liver's small bile ducts. Bile, a crucial digestive fluid produced by the liver, plays a vital role in processing food and expelling toxins, cholesterol, and aged red blood cells from the body. However, when these bile ducts suffer harm, bile accumulates in the liver, leading to irreversible scarring of liver tissue, a condition known as cirrhosis. Activated CD4 and CD8 lymphocytes drive the continual deterioration of these small and medium-sized bile ducts. In adults experiencing cholestasis (elevated levels of alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT)), suspicions of PBC arise once obstructive jaundice and systemic diseases have been ruled out through abdominal ultrasound. A confirmed diagnosis is made when disease-specific autoantibodies, such as antimitochondrial autoantibodies (AMA tit...

  Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic condition in which the liver's tiny bile ducts become damaged, inflamed, and eventually destroyed. Bile is a fluid made in the liver. It aids digestion and helps the body eliminate toxins, cholesterol and worn-out red blood cells. When the bile ducts are harmed, bile can back up in the liver, causing irreversible scarring of the liver tissue (cirrhosis). The continuous destruction of small and medium bile ducts is mediated by activated CD4 and CD8 lymphocytes. The prevalence of PBC has been estimated to be approximately 51 to 65 cases per 100,000 population in the United States. Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, ...